Buffett InvestorsNZX
Back
IFT.NZ

Infratil's Data Centre Bet Is Now Worth $15 Billion — And It Owns Half

The $12 Billion Infrastructure Giant Hiding in Plain Sight

Infratil might be one of the most misunderstood stocks on the NZX. At first glance, it looks like a staid infrastructure investment company — airports, telcos, renewable energy. But dig into the numbers and you'll find that Infratil is sitting on one of the most explosive AI-era assets in Australasia: its 49.72% stake in CDC Data Centres, which was just independently valued at A$15.0 billion.

Trading at around $12.07 NZD with a market cap of approximately $12 billion NZD, Infratil has quietly become one of the NZX's largest companies. Over the past year, shares have climbed from a 52-week low of $9.13 to near the 52-week high of $12.85 — a gain of over 30%.

The CDC Data Centres Story

Here's the headline number: Infratil's stake in CDC Data Centres is now worth approximately NZ$8.06 billion on its own. That's roughly two-thirds of Infratil's entire market cap, accounted for by a single asset.

The March 2026 independent valuation came in at A$15.0 billion — up A$1.0 billion in just three months from the December 2025 valuation of A$14.0 billion. That's a billion-dollar quarterly uplift driven by expanding data centre capacity and surging demand from AI and hyperscale computing customers.

CDC currently operates data centres across Australia and New Zealand with an installed capacity of 568 MW, with plans to scale to a staggering 1,820 MW by 2034. The growth runway here is enormous — CDC has confirmed new AI-related contracts, and the structural demand for data centre capacity shows no signs of slowing.

Infratil has committed to investing another A$250 million in CDC before the end of FY2026, betting even more heavily on the thesis.

Beyond Data Centres

While CDC grabs the headlines, Infratil's portfolio is genuinely diversified:

  • •One NZ (formerly Vodafone NZ): New Zealand's second-largest mobile network
  • •Wellington Airport: A core domestic travel hub
  • •Longroad Energy: US-based renewable energy developer
  • •Gurin Energy: Asia-focused renewable energy platform
  • •Qscan Group & RHCNZ: Diagnostic imaging businesses in Australia and NZ
  • •Mint Renewables: Australasian renewable generation

This diversification provides a floor under the valuation even if data centre enthusiasm cools.

Key Metrics

  • •Share price: ~$12.07 NZD
  • •Market cap: ~$12.0 billion NZD
  • •52-week range: $9.13 – $12.85
  • •Dividend yield: 1.75% (trailing), with $0.21 per share paid last year
  • •Forward EPS estimate: $0.31 NZD
  • •Analyst consensus: Buy

The dividend yield is modest at 1.75%, but Infratil has never been a yield play — it's a growth-through-asset-appreciation story. The real returns come from the rising value of its portfolio companies, particularly CDC.

What to Watch

  • •CDC valuation trajectory: The quarterly independent valuations are the single biggest driver of Infratil's share price. If AI-driven demand continues accelerating, the next valuation could push even higher.
  • •Asset sales or IPO: There's ongoing speculation about whether Infratil might eventually IPO part of its CDC stake. Any crystallisation event could unlock significant value.
  • •Interest rates: As an infrastructure investor, Infratil is sensitive to the cost of capital. Falling rates are a tailwind; rising rates are a headwind.
  • •One NZ performance: The telco business has been a steady contributor but faces intense competition from Spark and 2degrees.

The Bottom Line

Infratil is essentially an AI and infrastructure play wrapped in an NZX listing. The CDC Data Centres stake alone justifies a large chunk of the current market cap, and the valuation keeps climbing quarter after quarter. The risk is concentration — if data centre demand plateaus or valuations compress, Infratil's share price would feel it acutely. But for investors who believe AI-driven compute demand is a multi-decade trend, Infratil is one of the most direct ways to play it on the NZX.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*